Mechanism of action of interferon and ribavirin in treatment of hepatitis C
- PMID: 16107837
- DOI: 10.1038/nature04082
Mechanism of action of interferon and ribavirin in treatment of hepatitis C
Abstract
Since the identification of the hepatitis C virus, great strides have been made in the development of an antiviral therapy. As a crucial mediator of the innate antiviral immune response, interferon-alpha (IFN-alpha) was a natural choice for treatment. Whereas treatment with IFN-alpha alone achieved only modest success, the addition of the broad-spectrum antiviral agent ribavirin greatly improved responses. However, half of the infected individuals with chronic disease do not achieve sustained clearance of hepatitis C virus. To optimize current therapeutic strategies and to develop new therapies, a better understanding of the mechanism of action of IFN and ribavirin will be essential.
Similar articles
-
Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.J Med Virol. 2006 Jan;78(1):83-90. doi: 10.1002/jmv.20507. J Med Virol. 2006. PMID: 16299715
-
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.Nature. 2004 Dec 16;432(7019):922-4. doi: 10.1038/nature03153. Nature. 2004. PMID: 15602565
-
New therapeutic options for hepatitis C.Curr Opin Infect Dis. 2006 Dec;19(6):615-22. doi: 10.1097/QCO.0b013e328010a869. Curr Opin Infect Dis. 2006. PMID: 17075339 Review.
-
Hepatitis C kinetics: mathematical modeling of viral response to therapy.Semin Liver Dis. 2000;20(2):173-83. doi: 10.1055/s-2000-9940. Semin Liver Dis. 2000. PMID: 10946422 Review.
-
Chronic hepatitis C virus infection in renal transplant: treatment and outcome.Clin Transplant. 2006 Nov-Dec;20(6):677-83. doi: 10.1111/j.1399-0012.2006.00534.x. Clin Transplant. 2006. PMID: 17100715
Cited by
-
Structural aspects of hepatitis E virus.Arch Virol. 2022 Dec;167(12):2457-2481. doi: 10.1007/s00705-022-05575-8. Epub 2022 Sep 13. Arch Virol. 2022. PMID: 36098802 Free PMC article. Review.
-
Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin.J Antimicrob Chemother. 2015 Aug;70(8):2322-9. doi: 10.1093/jac/dkv122. Epub 2015 May 13. J Antimicrob Chemother. 2015. PMID: 25971261 Free PMC article. Clinical Trial.
-
Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response.PLoS One. 2012;7(7):e41209. doi: 10.1371/journal.pone.0041209. Epub 2012 Jul 24. PLoS One. 2012. PMID: 22911761 Free PMC article.
-
Liver-related effects of chronic hepatitis C antiviral treatment.World J Gastroenterol. 2020 Jun 14;26(22):2931-2947. doi: 10.3748/wjg.v26.i22.2931. World J Gastroenterol. 2020. PMID: 32587440 Free PMC article. Review.
-
Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection.Virol J. 2006 Jul 19;3:56. doi: 10.1186/1743-422X-3-56. Virol J. 2006. PMID: 16854226 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials